Niagen Bioscience, Inc.
NASDAQ: NAGE
Strong growth outlook and stabilizing technicals signal potential upside from current levels.
(Source: TradingView) 3-months Performance Profile of NAGE on a DTF compared to Dow Jones Industrial Average (DJI) and S&P 500 (SPX).
Niagen Bioscience reported strong FY25 results, with revenue rising 30% year-on-year to $129.4 million, driven by gro
🔒
Subscribers only
Sign in with your subscriber account or subscribe to access this research report.
Required subscription
Daily Digest
A$200.00
Already a subscriber?
Sign in to read this report.
Required subscription
Daily Digest
Stay informed with expert daily ASX research covering four carefully selected stocks, complete with market insights, risk ratings, and clear Buy, Hold, or Sell general guidance—delivered before the market opens each trading day.
- ✓ Four Expert-Selected ASX Stocks Daily
- ✓ Weekday Pre-Market Delivery
- ✓ In-Depth Research & Analysis
- ✓ Access to All Previous Reports
A$200.00/ 12 months
Risk:Medium
Subscribe Now →
